The official announcement for BioAsia 2026, the 23rd edition of Asia’s premier life sciences and health-tech forum, was released on Thursday by D. Sridhar Babu, Minister for IT, Electronics & Communications and Industries & Commerce in the presence of Sanjay Kumar, Special Chief Secretary, Industries, Commerce, ITE&C Departments; Shakthi M Nagappan,CEO, Telangana Life Sciences and other dignitaries. The summit is scheduled to be held from 16–18 February 2026 in Hyderabad. 

Over the past two decades, BioAsia has emerged as Asia’s foremost platform for life sciences, biopharma, health-tech, and medical innovation, consistently bringing together global leaders, investors, innovators, researchers, and policymakers. 

The 23rd edition of BioAsia is themed ‘ TechBio Unleashed: AI, Automation & the Biology Revolution.' The theme reflects the pivotal convergence of biology, data and deep technology that is reshaping drug discovery, diagnostics, manufacturing of therapies, and healthcare delivery globally. 

Speaking on the occasion, Minister D. Sridhar Babu said that as Telangana embarks its journey towards becoming a $3 Trillion Economy by 2047 , life sciences sector will play a critical role in shaping the growth of the state. Sanjay Kumar, Special Chief Secretary, Industries & Commerce and ITE &C mentioned  that BioAsia 2026 will provide a powerful platform for collaboration among startups, researchers, industry leaders and policymakers. 

Adding to this, Shakthi Nagappan, CEO, Telangana Life Sciences Foundation stated that “BioAsia 2026 comes at a pivotal moment when TechBio is redefining the very foundations of healthcare and life sciences. As biology converges with AI, automation and data, we see unprecedented opportunities for innovation, investment and impact, he said. 

The summit is expected to deliver strategic value for startups, researchers, investors, policymakers, and global organizations. 

All stakeholders are invited to participate in BioAsia 2026 from 16–18 February 2026 in Hyderabad to explore investment opportunities, foster collaborations and contribute to the TechBio revolution shaping the future of global healthcare.